{"entity":{"id":"solti","kind":"company","name":"SOLTI Cancer Research Group","aka":["SOLTI"],"tldr":"A Barcelona-based academic breast cancer group known for biomarker-driven trials that use PAM50 intrinsic subtypes to pick therapy.","summary":"Founded in 1995, SOLTI is a Spanish academic research group that designs translational breast cancer trials around molecular subtyping. PAMELA showed the HER2-enriched intrinsic subtype predicts response to dual HER2 blockade without chemotherapy, PATRICIA tested palbociclib with trastuzumab, and HARMONIA compares ribociclib with palbociclib in HER2-enriched luminal disease. SOLTI works closely with Vall d'Hebron and Hospital Clínic investigators, partners with the Breast International Group and industry, and runs window-of-opportunity and neoadjuvant designs with serial biopsies. Patient advocates sit on its scientific committee.","asOf":"2026-09-09","links":[{"label":"SOLTI","url":"https://www.gruposolti.org"}],"tags":["cooperative-group"],"related":["palbociclib","ribociclib","trastuzumab"],"cancers":["breast-hr-positive","breast-her2-positive","tnbc"],"sections":["targeted-therapy"],"technologies":["cdk46-inhibitor","rna-seq"],"targets":[],"drugs":[],"companies":["big","geicam"],"institutions":["vall-dhebron"],"pathways":[],"terms":["pam50"],"trials":[],"people":["mafalda-oliveira","eva-ciruelos"],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["PAM50-guided trials (PAMELA, HARMONIA)","CDK4/6 inhibitor trials (PATRICIA)","Window-of-opportunity and neoadjuvant designs","BIG member group"],"provenance":{"editedBy":"OnCo cooperative groups migration (row 251: institution consortium records moved to cooperative-group companies)","editedOn":"2026-09-25"},"hq":"Barcelona","country":"ES","companyType":"cooperative-group","website":"https://www.gruposolti.org","founded":1995,"investors":[],"funding":[]},"route":"/companies/solti/","neighbours":{"drug":[{"id":"palbociclib","kind":"drug","name":"Palbociclib","route":"/drugs/palbociclib/"},{"id":"ribociclib","kind":"drug","name":"Ribociclib","route":"/drugs/ribociclib/"},{"id":"trastuzumab","kind":"drug","name":"Trastuzumab","route":"/drugs/trastuzumab/"}],"cancer":[{"id":"breast-her2-positive","kind":"cancer","name":"HER2-positive breast cancer","route":"/cancers/breast-her2-positive/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"cdk46-inhibitor","kind":"technology","name":"CDK4/6 inhibitors","route":"/technologies/cdk46-inhibitor/"},{"id":"rna-seq","kind":"technology","name":"RNA sequencing & expression profiling","route":"/technologies/rna-seq/"}],"company":[{"id":"big","kind":"company","name":"Breast International Group (BIG)","route":"/companies/big/"},{"id":"geicam","kind":"company","name":"GEICAM Spanish Breast Cancer Group","route":"/companies/geicam/"}],"institution":[{"id":"vall-dhebron","kind":"institution","name":"Vall d'Hebron University Hospital / VHIO","route":"/institutions/vall-dhebron/"}],"term":[{"id":"pam50","kind":"term","name":"PAM50 / intrinsic subtypes","route":"/terms/pam50/"}],"person":[{"id":"aleix-prat","kind":"person","name":"Aleix Prat","route":"/people/aleix-prat/"},{"id":"cristina-saura","kind":"person","name":"Cristina Saura","route":"/people/cristina-saura/"},{"id":"eva-ciruelos","kind":"person","name":"Eva Ciruelos","route":"/people/eva-ciruelos/"},{"id":"mafalda-oliveira","kind":"person","name":"Mafalda Oliveira","route":"/people/mafalda-oliveira/"}]}}